
  
    
      
        
        
        PLoS_NNP Medicine_NNP is_VBZ a_DT sufficiently_RB new_JJ journal_NN that_IN we_PRP are_VBP often_RB doing_VBG
        something_NN for_IN the_DT first_JJ time_NN ._. This_DT issue_NN 's_POS “ first_NN” is_VBZ the_DT publication_NN of_IN a_DT research_NN article_NN
        that_IN reports_NNS data_NNS exclusively_RB from_IN animals_NNS ,_, more_RBR precisely_RB from_IN six_CD cynomolgus_JJ macaques_NNS
        used_VBN to_TO test_VB the_DT efficacy_NN of_IN a_DT new_JJ Lassa_NNP fever_NN vaccine_NN ._. There_EX is_VBZ no_DT question_NN that_IN animal_NN
        studies_NNS are_VBP an_DT important_JJ part_NN of_IN medical_JJ research_NN ,_, but_CC which_WDT ones_NNS ,_, if_IN any_DT ,_, belong_VB in_IN a_DT
        medical_JJ journal_NN ?_. More_JJR to_TO the_DT point_NN ,_, which_WDT ones_NNS belong_VBP in_IN 
        PLoS_NNP Medicine_NNP ?_. Although_IN our_PRP$ journal_NN 's_POS focus_NN is_VBZ on_IN human_JJ studies_NNS ,_, we_PRP have_VBP
        decided_VBN ,_, on_IN occasion_NN ,_, to_TO publish_VB animal_NN studies_NNS that_WDT have_VBP important_JJ and_CC proximal_NN
        implications_NNS for_IN clinical_JJ research_NN ,_, and_CC maybe_RB even_RB practice_VB ._.
        Lassa_NNP fever_NN causes_NNS serious_JJ morbidity_NN and_CC mortality_NN in_IN West_NNP Africa_NNP ._. The_DT virus_NN 's_POS natural_JJ
        hosts_NNS are_VBP rodents_NNS ,_, and_CC as_IN there_EX is_VBZ little_JJ chance_NN for_IN effective_JJ rodent_NN control_NN in_IN the_DT
        endemic_JJ areas_NNS ,_, a_DT vaccine_NN is_VBZ the_DT most_RBS feasible_JJ way_NN to_TO gain_VB control_NN of_IN the_DT disease_NN ._. Several_JJ
        research_NN groups_NNS around_IN the_DT world_NN have_VBP worked_VBN on_IN vaccine_NN development—and_NN their_PRP$ efforts_NNS have_VBP
        been_VBN boosted_VBN by_IN the_DT classification_NN of_IN Lassa_NNP virus_NN as_IN a_DT Category_NNP A_DT bioweapons_NNS agent—but_NN to_TO
        date_NN no_DT vaccine_NN is_VBZ available_JJ for_IN either_DT general_JJ or_CC high-risk_JJ application_NN in_IN humans_NNS ._.
        Thomas_NNP Geisbert_NNP and_CC colleagues_NNS have_VBP developed_VBN and_CC now_RB report_VB tests_NNS of_IN a_DT recombinant_JJ
        vaccine_NN based_VBN on_IN a_DT replication-competent_JJ vesicular_NN stomatitis_NNS virus_NN (_( DOI_NNP :_:
        10_CD ._. 1371_CD /_NN journal_NN ._. pmed_JJ ._. 0020183_CD )_) ._. One_CD shot_NN of_IN this_DT vaccine_NN protected_VBD four_CD out_IN of_IN four_CD
        vaccinated_JJ monkeys_NNS against_IN a_DT lethal_JJ virus_NN challenge_NN ,_, whereas_IN the_DT two_CD control_NN animals_NNS died_VBD ,_,
        making_VBG the_DT vaccine_NN a_DT serious_JJ candidate_NN for_IN future_JJ application_NN in_IN humans_NNS ._. Clearly_RB many_JJ
        issues_NNS about_IN this_DT vaccine_NN still_RB need_VBP to_TO be_VB resolved_VBN ,_, such_JJ as_IN vector_NN safety_NN ,_, duration_NN of_IN
        protection_NN ,_, and_CC breadth_NN of_IN protection_NN (_( there_RB are_VBP at_IN least_JJS four_CD distinct_JJ Lassa_NNP virus_NN
        strains_NNS )_) ._. Nevertheless_RB ,_, we_PRP accepted_VBD this_DT paper_NN because_IN we_PRP and_CC our_PRP$ advisers_NNS felt_VBD that_IN the_DT
        research_NN was_VBD at_IN a_DT stage_NN where_WRB clinical_JJ questions_NNS ,_, such_JJ as_IN patient_NN safety_NN and_CC design_NN of_IN
        early_JJ human_JJ trials_NNS ,_, should_MD inform_VB any_DT additional_JJ studies_NNS in_IN animals_NNS ._. The_DT proper_JJ place_NN for_IN
        such_JJ a_DT study_NN is_VBZ ,_, we_PRP believe_VBP ,_, a_DT clinical_JJ journal_NN ._.
        There_EX are_VBP several_JJ other_JJ types_NNS of_IN animal_NN studies_NNS we_PRP consider_VBP appropriate_JJ for_IN publication_NN
        in_IN 
        PLoS_NNP Medicine_NNP ._. These_DT include_VBP studies_NNS that_WDT explore_VBP off-label_JJ uses_NNS of_IN
        approved_VBN medical_JJ interventions_NNS in_IN validated_JJ animal_NN disease_NN models_NNS ,_, again_RB based_VBN on_IN the_DT
        studies_NNS '_POS direct_JJ relevance_NN to_TO potential_JJ treatment_NN of_IN human_JJ patients_NNS ._. More_RBR often_RB ,_, we_PRP would_MD
        publish_VB human_JJ studies_NNS that_WDT also_RB include_VBP experimental_JJ animal_NN data_NNS ,_, which_WDT typically_RB explore_VB
        molecular_JJ mechanisms_NNS suggested_VBN by_IN the_DT human_JJ data_NN ._.
        Animal_NNP studies_NNS that_WDT are_VBP submitted_VBN to_TO medical_JJ journals_NNS can_MD be_VB broadly_RB divided_VBN into_IN two_CD
        groups—_NN“ animal_NN clinical_JJ trials_NNS” and_CC exploratory_JJ studies_NNS ._. We_PRP will_MD assess_VB the_DT former_NN in_IN a_DT
        similar_JJ way_NN to_TO how_WRB we_PRP look_VBP at_IN human_JJ trials_NNS ._. This_DT assessment_NN will_MD include_VB not_RB only_RB the_DT
        ethical_JJ conduct_NN of_IN the_DT study_NN and_CC approval_NN by_IN the_DT respective_JJ regulatory_JJ authority_NN ,_, but_CC also_RB
        the_DT rigor_NN of_IN the_DT methodology_NN ._. Too_RB often_RB ,_, animal_JJ clinical_JJ trials_NNS ,_, i_NNP ._. e_SYM ._. ,_, prospective_JJ ,_,
        hypothesis-testing_JJ studies_NNS that_WDT evaluate_VBP the_DT effects_NNS of_IN a_DT health-related_JJ intervention_NN in_IN
        animals_NNS ,_, are_VBP not_RB performed_VBN with_IN the_DT same_JJ rigor_NN that_WDT has_VBZ been_VBN developed_VBN over_IN past_JJ decades_NNS
        and_CC widely_RB adopted_VBN by_IN the_DT clinical_JJ research_NN community_NN ._. In_IN particular_JJ ,_, animal_NN studies_NNS often_RB
        have_VBP inappropriate_JJ controls_NNS ,_, are_VBP underpowered_JJ ,_, involve_VB researchers_NNS monitoring_VBG outcomes_NNS who_WP
        are_VBP not_RB blinded_JJ to_TO treatment_NN allocation_NN ,_, or_CC lack_NN proper_JJ statistical_JJ analysis_NN ._.
        Exploratory_NNP studies_NNS ,_, designed_VBN to_TO yield_VB insight_NN into_IN disease_NN etiology_NN ,_, pathology_NN ,_, or_CC the_DT
        mechanisms_NNS by_IN which_WDT a_DT particular_JJ treatment_NN affects_VBZ a_DT disease_NN state_NN ,_, are_VBP a_DT crucial_JJ early_JJ
        part_NN of_IN the_DT translation_NN of_IN basic_JJ research_NN findings_NNS into_IN clinical_JJ practice_NN ._. However_RB ,_, by_IN and_CC
        large_JJ ,_, they_PRP will_MD not_RB be_VB appropriate_JJ for_IN 
        PLoS_NNP Medicine_NNP ._. Instead_RB ,_, we_PRP encourage_VBP submission_NN of_IN important_JJ advances_NNS
        from_IN this_DT early_JJ translational_NN stage_NN to_TO 
        PLoS_NNP Biology_NNP ,_, our_PRP$ flagship_NN open-access_JJ biology_NN journal_NN
        (_( www_NN ._. plosbiology_NN ._. org_NN )_) ._.
        It_PRP would_MD be_VB foolish_JJ to_TO deny_VB the_DT existence_NN of_IN a_DT sizeable_JJ “ grey_JJ area_NN” between_IN these_DT types_NNS
        of_IN study_NN ._. Between_IN our_PRP$ journals_NNS ,_, we_PRP will_MD try_VB to_TO provide_VB open-access_JJ publication_NN for_IN any_DT
        important_JJ study_NN at_IN this_DT interface_NN between_IN biology_NN and_CC medicine_NN ,_, and_CC will_MD be_VB happy_JJ to_TO talk_VB
        with_IN authors_NNS on_IN a_DT case-by-case_JJ basis_NN ._. In_IN addition_NN ,_, we_PRP currently_RB cross-reference_JJ studies_NNS
        between_IN the_DT two_CD journals—and_NN will_MD do_VB so_RB even_RB more_JJR when_WRB our_PRP$ new_JJ journals_NNS come_VBP on_IN line_NN ._. For_IN
        example_NN ,_, 
        PLoS_NNP Medicine_NNP has_VBZ published_VBN a_DT number_NN of_IN Perspectives_NNP on_IN research_NN articles_NNS
        published_VBN in_IN 
        PLoS_NNP Biology_NNP ,_, and_CC 
        PLoS_NNP Biology_NNP regularly_RB highlights_VBZ papers_NNS from_IN 
        PLoS_NNP Medicine_NNP on_IN its_PRP$ home_NN page_NN ._. In_IN this_DT way_NN ,_, because_IN all_DT our_PRP$ journals_NNS are_VBP
        open_JJ access_NN ,_, the_DT difference_NN to_TO the_DT reader_NN between_IN a_DT paper_NN published_VBN in_IN 
        PLoS_NNP Medicine_NNP and_CC any_DT other_JJ PLoS_NNP journal_NN ,_, is_VBZ just_RB a_DT rodent_NN click_NN ._.
      
    
  
